Cooley advised Spruce Biosciences on its $103.5 million initial public offering of 6,900,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Spruce, whose securities now trade on the Nasdaq Global Select Market under the symbol “SPBR,” is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Partners Jason Kent and Kristin VanderPas led the Cooley team.
